Neogen Chemicals Q4 FY26: Revenue up 22% to Rs 247 cr

What Neogen Chemicals reported in Q4 FY26

Neogen Chemicals Ltd (BOM:542665) reported a resilient operating performance for Q4 FY26, even as the broader chemical sector continued to face overcapacity and subdued end-market demand. Consolidated revenue from operations rose 21.57% year-on-year to Rs 246.56 crore, supported by improved volumes and sustained high plant utilisation. EBITDA increased 21% year-on-year to Rs 43.9 crore, while the EBITDA margin was largely stable at 17.8% versus 17.9% a year ago. Profit after tax for the quarter was reported at around Rs 11 crore, with one data point indicating Rs 11.39 crore. Management attributed the quarter’s performance to demand visibility across core products and volume growth in end-use applications such as pharma, flavours and fragrance, and other specialty applications.

Segment performance: organic and inorganic chemicals

Neogen’s segment mix in the quarter reflected a sharp divergence between organic and inorganic chemicals. The organic chemicals vertical recorded revenue of Rs 194 crore, up 7% year-on-year. In contrast, the inorganic chemicals segment delivered revenue of Rs 53 crore, marking a 145% year-on-year expansion, according to the earnings call commentary. The company said high utilisation across core plants helped offset the impact of supply chain disruptions and temporary costs related to the Dahej transition.

Cost pressures and how margins held up

The company said input costs such as packaging, material and logistics remained elevated, with geopolitical developments in the Middle East contributing to supply chain disruptions. It maintained that a strategic pass-through mechanism helped protect core profitability. In the reported financials for Q4 FY26, raw material costs were Rs 164.81 crore, marginally higher by 0.39% year-on-year. Employee expenses rose 10.32% year-on-year to Rs 20.2 crore.

A key pressure point was financing cost. Interest cost increased 71.76% year-on-year to Rs 21.47 crore, which the company linked to capex deployment for Neogen Ionics and the rebuild at Dahej. Depreciation expense increased 12.43% year-on-year to Rs 7.6 crore.

FY26 numbers: growth, margins, and cash flow swings

For FY26, consolidated revenue increased 10.85% year-on-year to Rs 861.96 crore. EBITDA for the year was Rs 137.3 crore, up 1% year-on-year, but the EBITDA margin moderated to 15.9% from 17.5% in FY25. Adjusted net profit for FY26 was Rs 28.75 crore, declining 33.36% year-on-year. Profit before tax for FY26 was Rs 41.08 crore, down 18.10% year-on-year.

Cash flow was a notable watchpoint in the year. Net cash flow from operating activities was negative Rs 231.48 crore in FY26, compared with positive Rs 195.98 crore in FY25. During the earnings call, the company highlighted that H2 FY26 operating cash flow turned positive at Rs 14.6 crore, versus an outflow of Rs 246.1 crore in H1 FY26, aided by improved operating efficiency and working capital management.

Debt, liquidity, and promoter support

Neogen’s consolidated total debt reached Rs 1,330 crore in FY26, taking net debt to Rs 1,295 crore. The company said the increase was driven by targeted funding for the Dahej facility rebuild and capital deployment at Neogen Ionics.

Promoters infused Rs 161 crore during the year to support expansion plans and battery materials capacity addition. On the insurance side related to the earlier Dahej incident, management said it received a tranche of Rs 60 crore in February 2026. It also stated cumulative insurance claims received were Rs 140 crore plus, along with salvage realisation of Rs 7 crore. Net lien receivable was disclosed at Rs 203 crore, with the company stating it was working with insurers to expedite final settlement.

Dahej incident context and current plant timelines

The company previously reported an exceptional loss of Rs 14.08 crore in Q4 FY25 and FY25 following a fire incident at its Dahej SEZ facility, including Multi-Purpose Plant (MPP3), tank farms and warehouse. Neogen said the insurance claim related to the incident has been admitted by the insurer.

On operations, management commentary indicated the Dahej replacement plant’s construction was progressing rapidly and commissioning remained on track for June 2026. Separately, the company also flagged project delays, including a Dahej replacement facility that is now expected to be completed by February 2027, as part of the risks investors are tracking.

Battery materials ramp-up: Neogen Ionics and customer progress

Neogen Ionics remained a key strategic focus as the company transitions towards a battery materials-led portfolio. Neogen Ionics contributed Rs 13 crore to Q4 FY26 revenue and Rs 36 crore for FY26. Management said it has received provisional approval from global customers for lithium electrolyte salts, indicating customer interest beyond India.

On capacity and customer readiness, management noted one customer increased capacity from 1 gigawatt to 5 gigawatts, which it expects to translate into higher volumes. It also said another customer approved Neogen for their pilot line, with commercial production expected in 2027. Timelines for the Pakhajan greenfield project were stated to be unchanged, with electrolyte commissioning expected in H1 FY27 and electrolyte salts in H2 FY27.

Guidance: FY27 revenue and longer-term targets

Neogen guided for standalone FY27 revenue in the range of Rs 875 crore to Rs 950 crore, and clarified that this guidance excludes the battery business. For the electrolyte business, management said revenue was around Rs 36 crore in FY26 and it expects to achieve Rs 300 crore plus in FY27, largely in the second half as more gigafactories come online.

Looking further out, the managing director said Neogen expects consolidated revenue to be between Rs 3,700 crore and Rs 4,200 crore by FY29, driven by utilisation of current capacities and potential additional investments in battery materials and other segments. In another guidance point shared on the call, management discussed a battery-related revenue trajectory, mentioning a possible run-rate above Rs 1,000 crore in FY28 and 2,400 to 2,900 crore by FY29, depending on electrolyte demand.

Capex and return expectations

Management explained that increased capex is linked to aligning technology with Morita and adding a 500 metric ton intermediate facility. Despite the increase, it stated that returns are expected to remain in the 18-20% range, supported by operational efficiencies and raw material savings. At the same time, the company flagged risks around liquidity if project ramp-ups and capacity utilisation face further delays.

Stock move and dividend

Neogen Chemicals shares rose 3.3% to Rs 1,720.46 after the Q4 FY26 update, according to the market report included in the provided text. The board recommended a final dividend of Re 1 per equity share for FY26.

Key numbers at a glance

Market impact and what investors are tracking

The quarter reinforced that Neogen’s core specialty chemical operations are still delivering volume-led growth despite an industry backdrop of overcapacity and demand softness across several sectors. Margin stability at 17.8% in Q4 FY26, alongside elevated interest costs and transition expenses, remains a key datapoint for investors watching fixed-cost absorption as new facilities scale.

The medium-term debate centres on execution and timelines. The company’s FY27 standalone guidance of Rs 875-950 crore provides visibility for the non-battery business, while the Rs 300 crore-plus FY27 target for the electrolyte business signals a steep ramp that is dependent on customer approvals and gigafactory commissioning schedules. Balance sheet monitoring is also central, given FY26 total debt of Rs 1,330 crore and the stated risk of liquidity strain if ramp-ups are delayed.

Conclusion

Neogen Chemicals closed Q4 FY26 with 22% year-on-year revenue growth to about Rs 247 crore and maintained EBITDA margin near 18% despite supply chain disruptions, transition costs and higher financing charges. FY27 is positioned as a key year, with commissioning milestones at Dahej and the Pakhajan greenfield battery materials facility expected to shape volumes and profitability. Investors will closely track facility ramp-ups, insurance claim settlement progress, and how quickly Neogen Ionics converts customer approvals into sustained commercial revenue.